Rabeprazole: a review of its use in acid-related gastrointestinal disorders (Q33768770)

29 July 2017

1 reference

title

Rabeprazole: a review of its use in acid-related gastrointestinal disorders (English)

1 reference

29 July 2017

2

A Markham

0 references

author name string

H D Langtry

series ordinal

1

1 reference

PubMed ID

10551440

29 July 2017

A Markham

series ordinal

2

1 reference

29 July 2017

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

58

1 reference

29 July 2017

4

1 reference

29 July 2017

725-742

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958040-00014

29 July 2017

0 references

cites work

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

1 reference

12 December 2020

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group

1 reference

12 December 2020

The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor

1 reference

12 December 2020

Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders

1 reference

12 December 2020

An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).

1 reference

12 December 2020

Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography

1 reference

12 December 2020

Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.

1 reference

12 December 2020

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

1 reference

12 December 2020

Review article: rabeprazole's profile in patients with gastrointestinal diseases

1 reference

12 December 2020

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

12 December 2020

Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole.

1 reference

12 December 2020

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

1 reference

12 December 2020

Proton-pump inhibitors in acid-related diseases.

1 reference

12 December 2020

Different biochemical modes of action of two irreversible H+,K(+)-ATPase inhibitors, omeprazole and E3810

1 reference

12 December 2020

Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.

1 reference

12 December 2020

Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor

1 reference

12 December 2020

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status

1 reference

12 December 2020

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

12 December 2020

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.

1 reference

12 December 2020

Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.

1 reference

12 December 2020

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

1 reference

12 December 2020

Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor

1 reference

12 December 2020

Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.

1 reference

12 December 2020

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

1 reference

12 December 2020

Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats

1 reference

12 December 2020

10.2165/00003495-199958040-00014

Identifiers

DOI

1 reference

PubMed ID

10551440

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10551440